New Trends in the Standard of Care for Initial Therapy of Acute Myeloid Leukemia

被引：28
作者：
Fernandez, Hugo F. [1 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL 33612 USA
来源：
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2010年
关键词：
D O I：
10.1182/asheducation-2010.1.56
中图分类号：
G40 [教育学];
学科分类号：
040101 ; 120403 ;
摘要：
In younger patients with acute myeloid leukemia (AML), initial treatment has provided very good control of the disease. Induction therapy has used combination chemotherapy, with anthracycline and cytarabine as the foundation. Recent trials support dose intensification of anthracycline in induction. Intensive postremission therapy further contributes to improving survival. The addition of targeted therapy with gemtuzumab ozogamicin to standard therapy has not improved on these outcomes. Newer agents targeted to specific molecular abnormalities or survival mechanisms in the leukemic cell are being studied as future additions to the current standard therapy.
引用
收藏
页码：56 / 61
页数：6
相关论文
共 48 条
[1]   Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia [J].
Allen, Steven L. ;
Kolitz, Jonathan E. ;
Lundberg, Ante S. ;
Bennett, John M. ;
Capizzi, Robert L. ;
Budman, Daniel R. .
LEUKEMIA RESEARCH, 2010, 34 (04) :487-491
[2]   Epigenetic therapies in haematological malignancies: Searching for true targets [J].
Altucci, Lucia ;
Minucci, Saverio .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (07) :1137-1145
[3]  
[Anonymous], 2008, Cancer facts figures 2008
[4]   BONE-MARROW TRANSPLANTATION OR CHEMOTHERAPY AFTER REMISSION INDUCTION FOR ADULTS WITH ACUTE NONLYMPHOBLASTIC LEUKEMIA - A PROSPECTIVE COMPARISON [J].
APPELBAUM, FR ;
DAHLBERG, S ;
THOMAS, ED ;
BUCKNER, CD ;
CHEEVER, MA ;
CLIFT, RA ;
CROWLEY, J ;
DEEG, HJ ;
FEFER, A ;
GREENBERG, PD ;
KADIN, M ;
SMITH, W ;
STEWART, P ;
SULLIVAN, K ;
STORB, R ;
WEIDEN, P .
ANNALS OF INTERNAL MEDICINE, 1984, 101 (05) :581-588
[5]   Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia [J].
Attar, Eyal C. ;
De Angelo, Daniel J. ;
Supko, Jeffrey G. ;
D'Amato, Ferdinando ;
Zahrieh, David ;
Sirulnik, Andres ;
Wadleigh, Martha ;
Ballen, Karen K. ;
McAfee, Steve ;
Miller, Kenneth B. ;
Levine, James ;
Galinsky, Ilene ;
Trehu, Elizabeth G. ;
Schenkein, David ;
Neuberg, Donna ;
Stone, Richard M. ;
Amrein, Philip C. .
CLINICAL CANCER RESEARCH, 2008, 14 (05) :1446-1454
[6]  
BERMAN E, 1991, BLOOD, V77, P1666
[7]   Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG [J].
Braess, Jan ;
Spiekermann, Karsten ;
Staib, Peter ;
Grueneisen, Andreas ;
Woermann, Bernhard ;
Ludwig, Wolf-Dieter ;
Serve, Hubert ;
Reichle, Albrecht ;
Peceny, Rudolf ;
Oruzio, Daniel ;
Schmid, Christoph ;
Schiel, Xaver ;
Hentrich, Marcus ;
Sauerland, Christina ;
Unterhalt, Michael ;
Fiegl, Michael ;
Kern, Wolfgang ;
Buske, Christian ;
Bohlander, Stefan ;
Heinecke, Achim ;
Baurmann, Herrad ;
Beelen, Dietrich W. ;
Berdel, Wolfgang E. ;
Buechner, Thomas ;
Hiddemann, Wolfgang .
BLOOD, 2009, 113 (17) :3903-3910
[8]   CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers [J].
Burger, J. A. ;
Peled, A. .
LEUKEMIA, 2009, 23 (01) :43-52
[9]  
BURNETT AK, 2009, BLOOD, V114, P484
[10]   The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 trial. [J].
Burnett, Alan K. ;
Kell, William J. ;
Goldstone, Anthony H. ;
Milligan, Donald ;
Hunter, Ann ;
Prentice, Archie G. ;
Russell, Nigel H. ;
Gibson, Brenda ;
Wheatley, Keith ;
Hills, Robert K. .
BLOOD, 2006, 108 (11) :8A-8A
12345